V-POINT study
Phase 3
Recruiting
- Conditions
- Gastric adenoma or early gastric cancer
- Registration Number
- JPRN-jRCTs041200045
- Lead Sponsor
- Furukawa Kazuhiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 124
Inclusion Criteria
Gastric adenoma or early gastric cancer patients planned for treatment by ESD, and those who take antithrombotics.
Exclusion Criteria
Those with simultaneous esophageal or duodenal endoscopic treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of bleeding within 8 weeks after ESD.
- Secondary Outcome Measures
Name Time Method 1. Frequency of GERD-like symptoms after ESD. <br>2. Frequency of pain after ESD.<br>3. Healing of the ulcer at 8 weeks after ESD. <br>4. Adverse events related to ESD.